{
  "asset": "RYBREVANT (amivantamab)",
  "query_terms": [
    "RYBREVANT (amivantamab)",
    "amivantamab",
    "RYBREVANT"
  ],
  "returned_unique": 24,
  "kept": 10,
  "studies": [
    {
      "nct_id": "NCT07276399",
      "title": "A Phase 3, Randomized, Open-Label, Multicenter Study of Amivantamab in Addition to Carboplatin and Pembrolizumab, Compared to Standard of Care Platinum and Pembrolizumab and 5-FU, in Participants With Treatment-Na√Øve Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma",
      "overall_status": "RECRUITING",
      "phase": "Phase 3",
      "conditions": [
        "Squamous Cell Carcinoma of Head and Neck"
      ],
      "lead_sponsor": "Janssen Research & Development, LLC",
      "collaborators": [],
      "interventions": [
        "Amivantamab",
        "Pembrolizumab",
        "Carboplatin",
        "5-Flurouracil",
        "Cisplatin"
      ],
      "last_update": "2025-12-19",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT07276399"
    },
    {
      "nct_id": "NCT07227025",
      "title": "A Phase 1/2 Study Evaluating the Safety and Efficacy of Amivantamab and Olomorasib Combination Therapy in Metastatic Non-small Cell Lung Cancer",
      "overall_status": "RECRUITING",
      "phase": "Phase 2",
      "conditions": [
        "Carcinoma, Non-Small-Cell Lung"
      ],
      "lead_sponsor": "Janssen Research & Development, LLC",
      "collaborators": [],
      "interventions": [
        "Amivantamab",
        "Olomorasib"
      ],
      "last_update": "2025-12-19",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT07227025"
    },
    {
      "nct_id": "NCT05379595",
      "title": "A Phase 1b/2, Open-Label Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer",
      "overall_status": "RECRUITING",
      "phase": "Phase 2",
      "conditions": [
        "Advanced or Metastatic Colorectal Cancer"
      ],
      "lead_sponsor": "Janssen Research & Development, LLC",
      "collaborators": [],
      "interventions": [
        "Amivantamab IV",
        "Fluorouracil",
        "Leucovorin",
        "Oxaliplatin",
        "Irinotecan",
        "Amivantamab"
      ],
      "last_update": "2025-12-19",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT05379595"
    },
    {
      "nct_id": "NCT06662786",
      "title": "A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer",
      "overall_status": "RECRUITING",
      "phase": "Phase 3",
      "conditions": [
        "Colorectal Neoplasms"
      ],
      "lead_sponsor": "Janssen Research & Development, LLC",
      "collaborators": [],
      "interventions": [
        "Amivantamab",
        "Cetuximab",
        "5-fluorouracil",
        "Leucovorin calcium/Levoleucovorin",
        "Oxaliplatin",
        "Irinotecan Hydrochloride"
      ],
      "last_update": "2025-12-19",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT06662786"
    },
    {
      "nct_id": "NCT04965090",
      "title": "A Phase 2 Single-Arm Study of Amivantamab (JNJ-61186372) and Lazertinib in Metastatic EGFR-mutant Lung Cancer With Progressive or New CNS Metastases on Previous Treatment",
      "overall_status": "COMPLETED",
      "phase": "Phase 2",
      "conditions": [
        "Metastatic Non Small Cell Lung Cancer",
        "Recurrent Non Small Cell Lung Cancer"
      ],
      "lead_sponsor": "Memorial Sloan Kettering Cancer Center",
      "collaborators": [
        "Janssen Scientific Affairs, LLC"
      ],
      "interventions": [
        "Amivantamab",
        "Lazertinib"
      ],
      "last_update": "2025-12-18",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT04965090"
    },
    {
      "nct_id": "NCT04077463",
      "title": "An Open-label Phase 1/1b Study to Evaluate the Safety and Pharmacokinetics of JNJ-73841937 (Lazertinib), a Third Generation EGFR-TKI, as Monotherapy or in Combinations With JNJ-61186372, a Human Bispecific EGFR and cMet Antibody in Participants With Advanced Non-Small Cell Lung Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "Phase 1",
      "conditions": [
        "Carcinoma, Non-Small-Cell Lung"
      ],
      "lead_sponsor": "Janssen Research & Development, LLC",
      "collaborators": [],
      "interventions": [
        "Lazertinib",
        "Amivantamab",
        "Carboplatin",
        "Pemetrexed"
      ],
      "last_update": "2025-12-24",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT04077463"
    },
    {
      "nct_id": "NCT06385080",
      "title": "A Phase 1b/2, Open-label Study of Amivantamab Monotherapy and Amivantamab in Addition to Other Therapeutic Agents in Participants With Head and Neck Squamous Cell Carcinoma",
      "overall_status": "RECRUITING",
      "phase": "Phase 2",
      "conditions": [
        "Squamous Cell Carcinoma of Head and Neck"
      ],
      "lead_sponsor": "Janssen Research & Development, LLC",
      "collaborators": [],
      "interventions": [
        "Amivantamab",
        "Pembrolizumab",
        "Paclitaxel",
        "Carboplatin"
      ],
      "last_update": "2025-12-19",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT06385080"
    },
    {
      "nct_id": "NCT04538664",
      "title": "A Randomized, Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Patients With EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "Phase 3",
      "conditions": [
        "Carcinoma, Non-Small-Cell Lung"
      ],
      "lead_sponsor": "Janssen Research & Development, LLC",
      "collaborators": [],
      "interventions": [
        "Amivantamab",
        "Pemetrexed",
        "Carboplatin",
        "Pemetrexed"
      ],
      "last_update": "2025-12-23",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT04538664"
    },
    {
      "nct_id": "NCT05498428",
      "title": "A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients With Advanced or Metastatic Solid Tumors Including EGFR-mutated Non-Small Cell Lung Cancer",
      "overall_status": "RECRUITING",
      "phase": "Phase 2",
      "conditions": [
        "Carcinoma, Non-small-Cell Lung"
      ],
      "lead_sponsor": "Janssen Research & Development, LLC",
      "collaborators": [],
      "interventions": [
        "Amivantamab",
        "Lazertinib",
        "Carboplatin",
        "Pemetrexed",
        "Direct Oral Anticoagulant (DOAC)",
        "Low Molecular Weight Heparin (LMWH)"
      ],
      "last_update": "2025-12-19",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT05498428"
    },
    {
      "nct_id": "NCT05388669",
      "title": "A Phase 3, Open-label, Randomized Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Patients With EGFR-mutated Advanced or Metastatic Non-small Cell Lung Cancer After Progression on Osimertinib and Chemotherapy",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "Phase 3",
      "conditions": [
        "Advanced or Metastatic Non-small Cell Lung Cancer"
      ],
      "lead_sponsor": "Janssen Research & Development, LLC",
      "collaborators": [],
      "interventions": [
        "Lazertinib",
        "Amivantamab Subcutaneous and Co-Formulated with Recombinant Human Hyaluronidase (SC CF)",
        "Amivantamab Intravenous"
      ],
      "last_update": "2025-12-19",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT05388669"
    }
  ]
}